SG11201906671SA - Compositions and methods for inhibiting reticulon 4 - Google Patents

Compositions and methods for inhibiting reticulon 4

Info

Publication number
SG11201906671SA
SG11201906671SA SG11201906671SA SG11201906671SA SG11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA
Authority
SG
Singapore
Prior art keywords
international
co7c
compositions
methods
oakland
Prior art date
Application number
SG11201906671SA
Other languages
English (en)
Inventor
Daniel Nomura
James Olzmann
Leslie Bateman
Truc Nguyen
David Miyamoto
Tucker Huffman
Allison Roberts
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11201906671SA publication Critical patent/SG11201906671SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/27Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/09Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201906671SA 2017-02-03 2018-02-02 Compositions and methods for inhibiting reticulon 4 SG11201906671SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762454681P 2017-02-03 2017-02-03
US201762471865P 2017-03-15 2017-03-15
PCT/US2018/016650 WO2018144870A1 (fr) 2017-02-03 2018-02-02 Compositions et méthodes permettant d'inhiber l'inhibiteur reticulon 4

Publications (1)

Publication Number Publication Date
SG11201906671SA true SG11201906671SA (en) 2019-08-27

Family

ID=63040209

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906671SA SG11201906671SA (en) 2017-02-03 2018-02-02 Compositions and methods for inhibiting reticulon 4

Country Status (11)

Country Link
US (1) US20200062696A1 (fr)
EP (1) EP3576728A4 (fr)
JP (1) JP2020506935A (fr)
KR (1) KR20190126074A (fr)
CN (1) CN110461322A (fr)
AU (1) AU2018215447A1 (fr)
BR (1) BR112019016132A2 (fr)
CA (1) CA3051587A1 (fr)
MX (1) MX2019009200A (fr)
SG (1) SG11201906671SA (fr)
WO (1) WO2018144870A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020039094A1 (fr) * 2018-08-24 2020-02-27 Xeniopro GmbH Éthers phénoxy(hétéro)aryle à activité antiproliférative
CA3162348A1 (fr) * 2019-12-24 2021-07-01 Nathanael S. Gray Inhibiteurs du facteur de transcription a domaine associe transcriptionnel ameliore (tead) et leurs utilisations
CN119318708B (zh) * 2024-10-15 2025-10-10 中国科学技术大学 Eya3作为靶点在宫颈癌治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102790A (en) * 1991-09-17 1996-01-31 Roussel Uclaf 3-Cycloalkyl-prop-2- enamide derivatives
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
US7928127B2 (en) * 2005-05-19 2011-04-19 Notre Dame University Inhibitors of matrix metallaproteinases
US8828390B2 (en) * 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
WO2012164103A2 (fr) * 2011-06-03 2012-12-06 Universität Zürich Bloqueurs de la voix nogo-a s1pr pour le traitement de maladies caractérisées par une lésion neuronale et un défaut de réparation ultérieure
MX353205B (es) * 2011-08-03 2018-01-08 Univ Nat Taiwan Agonistas de proteína-tirosina-fosfatasa-1 que contiene homología src-2 y métodos de tratamiento que usan los mismos.
CN104203242B (zh) * 2012-04-04 2017-03-15 杭州德润玉成生物科技有限公司 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂
US10782295B2 (en) * 2013-08-13 2020-09-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
CN106029632B (zh) * 2014-02-28 2019-06-21 国立大学法人东北大学 酰胺衍生物
EP3131875A4 (fr) * 2014-04-16 2018-04-04 Nanyang Technological University Allénamide formant poignée orthogonale pour une modification sélective de la cystéine dans des peptides et des protéines
EP3247353A4 (fr) * 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Inhibiteurs d'itk hétérocycliques pour traiter l'inflammation et le cancer
EP3365686A4 (fr) * 2015-10-22 2019-03-27 The Scripps Research Institute Sondes réactives à la cystéine et utilisations associées

Also Published As

Publication number Publication date
JP2020506935A (ja) 2020-03-05
AU2018215447A1 (en) 2019-08-08
EP3576728A1 (fr) 2019-12-11
CA3051587A1 (fr) 2018-08-09
MX2019009200A (es) 2019-10-21
US20200062696A1 (en) 2020-02-27
WO2018144870A1 (fr) 2018-08-09
BR112019016132A2 (pt) 2020-04-07
EP3576728A4 (fr) 2020-08-12
CN110461322A (zh) 2019-11-15
WO2018144870A8 (fr) 2019-09-06
KR20190126074A (ko) 2019-11-08

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201900501RA (en) Cannabis composition
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201906395PA (en) Blockchain based data processing method and device
SG11201900596XA (en) Cannabis composition
SG11201804041QA (en) High conductivity graphane-metal composite and methods of manufacture
SG11202000131VA (en) Substituted aluminum nitride for improved acoustic wave filters
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201803906PA (en) Control of cellular redox levels
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201806992VA (en) Antibodies to tigit
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201900665VA (en) Cannabis composition
SG11201805493YA (en) Binding members with altered diversity scaffold domains
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201805164WA (en) Programmable universal quantum annealing with co-planar waveguide flux qubits
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201810525XA (en) Anti-gitr antibodies and uses thereof